Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer Clinical Trial

Official title:
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Status Recruiting

Clinical Trial Summary

Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers. Advanced esophageal carcinoma have poor prognosis and majority of patients resistant to chemotherapy in China. In the investigators phase II clinical trial proceeded before,the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal carcinoma. The investigators then initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01336049
Study type	Interventional
Source	Peking University
Contact	xiaodong zhang, MD
Phone	86-01-88196175
Email	zxd0829@yahoo.com.cn
Status	Recruiting
Phase	Phase 2
Start date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Terminated	`NCT01627379` - Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer	Phase 3
Recruiting	`NCT05945823` - Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors	Phase 2
Recruiting	`NCT04804696` - Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT02016274` - Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer	Phase 2
Recruiting	`NCT02016287` - Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer	Phase 2
Active, not recruiting	`NCT01351103` - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase 1
Recruiting	`NCT01993784` - Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.	Phase 1/Phase 2